Mavrilimumab
As of the edition of 20 October 2026, Mavrilimumab is an antibody: went quiet in 2020; acts on CSF2RA and CSF2RB.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2020
- Kind
- Antibody
- Registered trials
- 7, 1 stopped early
- Disease areas
- Bones, joints and muscles; Immune system; Skin and connective tissue; Infections; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company-target row on route A because of this drug.
Companies on route A for this drug
In the product1 company-target row is on route A because of Mavrilimumab.
See the 1 company-target row on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 6 | 4 | 0 | 1 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| AstraZeneca | Lead sponsor of trials | 2010 to now |